Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of hypotension during anesthesia,Treatment of mild to moderate hypotension,Treatment of supraventricular tachycardia (off-label),Nasal decongestant (topical use)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/m L (10 mg in 100 m L NS) or 200 mcg/m L (20 mg in 100 m L NS). Administer via central line preferred.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life: 2-3 hours; clinical context: requires repeated dosing or continuous infusion for sustained effect.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Primarily metabolized by monoamine oxidase (MAO) and sulfotransferase in the liver and gastrointestinal tract; subject to first-pass metabolism.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Primarily renal (80-90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Volume of distribution: 2-4 L/kg; clinical meaning: extensive tissue distribution with limited CNS penetration.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: <1% due to extensive first-pass metabolism; intranasal: up to 50% (variable); IM/SC: 100% bioavailable.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No dose adjustment required for GFR >15 m L/min. For GFR <15 m L/min or on dialysis: use with caution; no specific dose adjustment guidelines; monitor blood pressure and adjust infusion rate accordingly due to potential reduced clearance.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A: no adjustment. Child-Pugh B and C: consider starting at lower infusion rates (e.g., 50-100 mcg/min) and titrate carefully due to reduced clearance and increased sensitivity.
No dosage adjustment required for hepatic impairment.
Intravenous infusion: 0.5-1 mcg/kg/min, titrate to effect; maximum 10 mcg/kg/min. Administer via central line preferred. For bolus: 0.5-1 mcg/kg every 10-15 min as needed (off-label; use with caution).
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients may have increased sensitivity; start at lower infusion rates (e.g., 50-100 mcg/min) and titrate slowly; monitor blood pressure closely due to risk of hypertension and bradycardia.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May cause severe hypertension, bradycardia, or arrhythmias; use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis; extravasation may cause tissue necrosis.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to phenylephrine; severe hypertension; ventricular tachycardia; narrow-angle glaucoma; concurrent use with MAO inhibitors or within 14 days of MAOI therapy.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No known food interactions with intravenous phenylephrine. Maintain usual diet unless directed otherwise by your healthcare provider.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Phenylephrine is a sympathomimetic amine used as a vasopressor. For the first trimester, there is no evidence of increased risk of major congenital malformations based on human data, although animal studies are limited. For the second and third trimesters, maternal use may reduce uteroplacental blood flow due to vasoconstriction, potentially causing fetal hypoxia and bradycardia. It is generally avoided in pregnancy unless clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Phenylephrine is excreted into breast milk in minimal amounts, with an estimated M/P ratio of approximately 0.2. The relative infant dose is low (<1% of maternal weight-adjusted dose). Oral bioavailability is poor, making significant exposure to the infant unlikely. However, use with caution, especially in preterm infants or those with cardiovascular instability.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy may increase plasma volume and cardiac output, but phenylephrine pharmacokinetics are not significantly altered. Dose adjustments are primarily based on maternal blood pressure response. Typically, no routine dose adjustment is required, but careful titration is recommended due to potential for exaggerated hypertension or decreased placental perfusion.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Phenylephrine hydrochloride in 0.9% sodium chloride is used for the prevention and treatment of hypotension during anesthesia. Administer via IV infusion with careful titration to avoid reflex bradycardia. Monitor blood pressure continuously, especially in patients with preexisting hypertension or bradyarrhythmias. Use with caution in patients with hyperthyroidism, severe atherosclerosis, or narrow-angle glaucoma. Not recommended for patients with severe hypertension or ventricular tachycardia. In obstetrics, may decrease uterine blood flow; use only if clearly needed.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This medication is given intravenously to raise your blood pressure during surgery or medical procedures.,Inform your healthcare provider if you have high blood pressure, heart problems, thyroid disease, or glaucoma.,Tell your doctor about all medications you are taking, especially MAO inhibitors, antidepressants, or other blood pressure medications.,Report any chest pain, slow heartbeat, headache, or difficulty breathing during the infusion.,This medication is not for self-administration; it is given only in a hospital setting.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Dosulepin, a tricyclic antidepressant, inhibits the reuptake of norepinephrine, leading to increased synaptic norepinephrine concentrations. This potentiates the vasopressor effects of phenylephrine, a direct-acting alpha-1 adrenergic receptor agonist, resulting in an exaggerated hypertensive response and increased risk of cardiac arrhythmias. Clinically, this interaction can cause severe hypertension, reflex bradycardia, and potential cardiovascular complications."
"Phenylephrine, a selective α1-adrenergic receptor agonist, can potentiate the hypertensive effects of pirlindole, a monoamine oxidase inhibitor (MAOI) with non-selective MAO-A and MAO-B inhibition. This combination increases the risk of a hypertensive crisis due to excessive norepinephrine accumulation at sympathetic nerve terminals. Patients may experience severe hypertension, headache, palpitations, and potential intracranial hemorrhage."
"Phenylephrine, a selective α1-adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Methylergometrine, an ergot alkaloid, stimulates smooth muscle contraction via serotonergic (5-HT2) and α-adrenergic receptors, primarily used to prevent postpartum hemorrhage. Concurrent use may lead to additive or synergistic vasopressor effects, resulting in severe hypertension, potential hypertensive crisis, and increased risk of cerebrovascular or cardiac events such as stroke or myocardial ischemia."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is: Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/m L (10 mg in 100 m L NS) or 200 mcg/m L (20 mg in 100 m L NS). Administer via central line preferred.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is classified as Category A/B. Phenylephrine is a sympathomimetic amine used as a vasopressor. For the first trimester, there is no evidence of increased risk of major congenital malformations based on human dat. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.